Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Guillem Argiles"'
Autor:
Paolo Nuciforo, Isabel Puig, Jordi Rodon, Ana Vivancos, Oriol Arqués, Aleix Prat, Ginevra Caratu, Hector G. Palmer, Eloy Espin, Irene Chicote, Ramón Charco, Rodrigo Dienstmann, Daniel Silberschmidt, Judit Matito, Guillem Argiles, Wenlin Shao, Stefania Landolfi, Stephan P. Tenbaum, Natalia Fernandez, Josep Tabernero
Publikováno v:
Clinical Cancer Research. 22:644-656
Purpose: Oncogenic mutations in the KRAS/PI3K/AKT pathway are one of the most frequent alterations in cancer. Although PI3K or AKT inhibitors show promising results in clinical trials, drug resistance frequently emerges. We previously revealed Wnt/β
Autor:
Enrique Sanz-Garcia, Jordi Rodon, Marta Vilaro, Ignacio Matos, Ana Vivancos, Hector G. Palmer, Rodrigo Dienstmann, Josep Tabernero, Teresa Macarulla, Ariadna Garcia, Jaume Capdevila, Elena Elez, Maria Alsina, Paolo Nuciforo, Cristina Viaplana, Helena Verdaguer, Carolina Ortiz, Guillem Argiles, Tamara Sauri, Fiorella Ruiz-Pace, Stefania Landolfi
Publikováno v:
Scientia
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Molecular Oncology
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Molecular Oncology
Colorectal cancer; Driver gene; Mutant allele fraction Càncer colorectal; Gen conductor; Fracció d'al·lel mutant Cáncer colorrectal; Gen conductor; Fracción de alelo mutante Sequencing of tumors is now routine and guides personalized cancer ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::269aeba798abfc842052996d310bb627
https://hdl.handle.net/11351/3849
https://hdl.handle.net/11351/3849
Autor:
Ann M. Swift, Shilpa Gupta, Pamela N. Munster, Jonathan D. Cheng, Olav Dajani, Ruixue Wang, Antoine Hollebecque, Guillem Argiles, Sarina Anne Piha-Paul, Alessandra Tosolini
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 21(23)
Purpose: The PI3K/Akt/mTOR signaling pathway is aberrantly activated in many cancers. Combining ridaforolimus, an mTOR inhibitor, with MK-2206, an Akt inhibitor, may more completely block the PI3K pathway and inhibit tumor growth. Experimental Design
Autor:
Livio Trusolino, Guillem Argiles, Martín A. Rivas, Violeta Serra, Hector G. Palmer, Claudia Aura, Celina Garcia-Garcia, Josep Tabernero, Ana Vivancos, Pilar Anton, Irene Chicote, Olga Rodriguez, Paolo Nuciforo, Judit Grueso, Marta Guzman, José Baselga, Katti Jessen, Rodrigo Dienstmann, Maria Teresa Calvo, Andrea Bertotti, Albert Gris-Oliver, Judit Matito, Yasir H. Ibrahim, Maurizio Scaltriti
Purpose: PI3K pathway activation occurs in concomitance with RAS/BRAF mutations in colorectal cancer, limiting the sensitivity to targeted therapies. Several clinical studies are being conducted to test the tolerability and clinical activity of dual
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5acc15bdd990291cd1817b36418909b6
http://hdl.handle.net/2318/1559118
http://hdl.handle.net/2318/1559118
Autor:
Thorunn Helgason, Douglas Bootle, David Demanse, Cornelia Quadt, Ana M. Gonzalez-Angulo, Guillem Argiles, Markus Boehm, Timothy K. Goggin, Martin Schuler, Robin M.J.M. van Geel, Howard A. Burris, Jordan Berlin, José Baselga, Jan H.M. Schellens, Dejan Juric, Mark R. Middleton
2531 Background: BYL719 is an oral small-molecule inhibitor of the p110α catalytic subunit of phosphatidylinositol 3-kinase (PI3K), which is encoded by the PIK3CA gene, one of the most commonly mutated genes in human cancers. BYL719 inhibits prolife
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f376c02364f15373beb5a727de75f5b9
Autor:
Ana Maria Martinez de Castro, Paolo Nuciforo, Irene Brana, Ana Vivancos, Cinta Hierro, Cristina Saura, Ana Oaknin, Jordi Rodon Ahnert, Maria Ochoa de Olza, Rodrigo Dienstmann, Juan Martin Liberal, Analia Azaro, Cristina Cruz Zambrano, Josep Tabernero, Mafalda Oliveira, Helena Aguilar, Guillem Argiles, Elena Sanchez
Publikováno v:
Journal of Clinical Oncology. 34:2572-2572
2572Background: Drugs targeting aberrations in the PAM pathway are in clinical development but it is not completely clear if mut and ttx matching increases chances of ClinBen. Methods: Retrospectiv...
Autor:
D. Marino, Jordi Rodon, R. Dienstmann, Cristina Cruz, B. Adamo, Analia Azaro, Guillem Argiles, Maria Alsina, A. Garrido-Castro, J. Tabernero, Jose Manuel Trigo Perez, Cinta Hierro, M. Berzosa
Publikováno v:
European Journal of Cancer. 50:124
Autor:
Alessandra Tosolini, Antoine Hollebecque, Jonathan D. Cheng, Olav Dajani, Shilpa Gupta, Ann M. Swift, Sarina Anne Piha-Paul, Pamela N. Munster, Guillem Argiles
Publikováno v:
Journal of Clinical Oncology. 32:2509-2509
2509 Background: The PI3K/AKT/mTOR signaling pathway is aberrantly activated in a variety of cancers. The combination of ridaforolimus (mTOR inhibitor) and MK-2206 may lead to blockade of the PI3K ...
Autor:
Alessandra Tosolini, Ruixue Wang, Guillem Argiles, Pamela N. Munster, Olav Dajani, Jonathan D. Cheng, Ann M. Swift, Sarina Anne Piha-Paul, Shilpa Gupta, Antoine Hollebecque
Publikováno v:
Journal of Clinical Oncology. 32:2601-2601
2601 Background: The PI3K/AKT/mTOR signaling pathway is aberrantly activated in a variety of cancers. Ridaforolimus (R) is an mTOR inhibitor with activity in a broad range of cancers. MK-0752 inhib...
Autor:
Ann M. Swift, Ruixue Wang, Tormod Kyrre Guren, Shilpa Gupta, Antoine Hollebecque, Sarina Anne Piha-Paul, Guillem Argiles, Alessandra Tosolini, Jonathan D. Cheng, Pamela N. Munster
Publikováno v:
Annals of Oncology. 25:i25